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Cardiovascular diseaseThe successful roll-out of highly active antiretroviral therapy (HAART) has extended life expectancy and en-
hanced the overall well-being of HIV-positive individuals. There are, however, increased concerns regarding
HAART-mediated metabolic derangements and its potential risk for cardiovascular diseases (CVD) in the long-
term. Here certain classes of antiretroviral drugs such as the HIV protease inhibitors (PIs) are strongly implicated
in this process. This article largely focuses on the direct PI-linked development of cardio-metabolic complications,
and reviews the inter-linked roles of oxidative stress and the ubiquitin–proteasome system (UPS) as key medi-
ators driving this process. It is proposed that PIs trigger reactive oxygen species (ROS) production that leads to
serious downstream consequences such as cell death, impaired mitochondrial function, and UPS dysregulation.
Moreover, we advocate that HIV PIs may also directly lower myocardial UPS function. The attenuation of cardiac
UPS can initiate transcriptional changes that contribute to perturbed lipid metabolism, thereby fueling a pro-
atherogenic milieu. It may also directly alter ionic channels and interfere with electrical signaling in themyocar-
dium. Therefore HIV PI-induced ROS together with a dysfunctional UPS elicit detrimental effects on the cardio-
vascular system that will eventually result in the onset of heart diseases. Thus while HIV PIs substantially
improve life expectancy and quality of life in HIV-positive patients, its longer-term side-effects on the cardiovas-
cular system should lead to a) greater clinical awareness regarding its beneﬁt–harm paradigm, and b) the devel-
opment and evaluation of novel co-treatment strategies.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Human immunodeﬁciency virus (HIV) infections have surged dur-
ing the last two decades, withmore than ﬁve out of the 40 million glob-
ally infected individuals currently residing in sub-Saharan Africa [1,2].
The subsequent development of acquired immune deﬁciency syndrome
(AIDS) decreases the quality of life amongst sufferers and places their
long-term health in jeopardy. However, the successful roll-out of highly
active antiretroviral therapy (HAART) has extended life expectancy and
also enhanced the overall well-being of HIV-positive individuals [3,4].
For example, an extensive study comprising of 41, 213 HIV-infected pa-
tients exposed to HAART for ≥72 months revealed that antiretrovirals
(ARVs) signiﬁcantly improved death rate compared toHAART-naïve pa-
tients, i.e. 20.9 versus 5.2 deaths per 100 person-years observation [5].
There are, however, increased concerns regarding HAART-mediated
metabolic derangements and its potential risk for cardiovascular dis-
eases (CVD) in the long-term. Here certain classes of ARV drugs such
as the HIV protease inhibitors (PIs) are implicated in this process, al-
though mechanistic insight remains incomplete. Together with the27 21 808 3145.
ights reserved.rising obesity ‘epidemic’ that is strongly linked to the increased devel-
opment of cardio-metabolic complications, this scenario constitutes a
‘dual burden’ of disease especially in developing countries. This article
focuses on HAART-linked onset of cardio-metabolic complications,
with emphasis on the direct damaging role of PIs, and also reviews the
inter-linked roles of oxidative stress and the ubiquitin–proteasome sys-
tem (UPS) as key mediators driving this process.2. The link between HIV infection and cardiovascular diseases
HIV infection is characterized by a compromised immune system,
subsequent chronic inﬂammation, and the development of AIDS.
Cardiac abnormalities in HIV-positive persons were noted as early as
1989 [6,7] (pre-HAART era) and included dilated cardiomyopathy,
endo-, myo- and peri-carditis, and pulmonary hypertension [6–9].
Here HIV may trigger direct and indirect (e.g. inﬂammation) mecha-
nisms that may eventually impair cardiac contractile function. HIV is
able to directly infect cardiac tissue [10], though this may be dependent
on the stage of the disease. However, the direct mechanisms whereby
HIV may damage the heart remain relatively poorly understood and
will therefore not be a focus of this review article.
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and some studies emphasized its role as a crucial factor in HIV-mediated
onset of heart diseases. For example, Becker et al. [11] found that HIV-
infected HAART naïve patients with acute coronary syndrome (ACS) ex-
hibited less traditional CVD risk factors than their HIV-negative counter-
parts (with ACS). Moreover, such individuals displayed a signiﬁcantly
higher thrombotic burden and distinct angiographic characteristics.
Similar results were reported by other studies [12,13] and the data
point towards a distinct pathogenesis of cardiovascular abnormalities
in HIV-infected compared to healthy individuals. Here HIV-positive pa-
tients with ACS were compared to HIV-negative and diabetic non-ACS
counterparts, and although the extent of multi-vessel disease in all
three groups was similar, HIV-positive individuals were much younger
and exhibited less complex lesions thanmatched controls [11]. Further-
more, the degree of subclinical coronary atherosclerosis was elevated
within the HIV-infected population [13]. Therefore the nature of HIV
itself allows for viral-mediated activation of pathways (especially in-
ﬂammatory) that contribute to the development of thrombotic and ath-
erosclerotic disease progression in addition to the traditional risk factor
pathways. However, this is not themajor objective of the current review
article; instead our focus is on HAART-linked onset of cardio-metabolic
complications, with particular emphasis on the direct damaging role of
PIs.
3. HIV PIs and the onset of cardio-metabolic complications
ARVs inhibit the viral lifecycle at key stages and the combination of
different drug classes (as HAART) constitutes critical weaponry in the
ﬁght against HIV/AIDS (Fig. 1). PIs act by inhibiting HIV aspartyl prote-
ase leading to the production of immature and non-infectious viralFig. 1.HIV lifecycle and antiretroviral drug targets. 1. The virus docks and inﬁltrates the cell me
transcriptase transcribes single-stranded RNA; 4. Production of double-stranded RNA; 5. RNA e
transcription system allows viral mRNA production for viral proteins; and 7. Gag and Gag-pol
proteins and mature viral particles. HAART can inhibit key viral enzymes at various stages o
nucleoside reverse transcriptase inhibitors (NRTI, NNRTI), integrase inhibitors and protease inhparticles [14]. Several HIV-PI-type drugs were developed since the ad-
vent of HAART in 1995 [15], with Lopinavir/Ritonavir widely used glob-
ally and currently the only available PI in South African clinics (HIV PIs
with side-effects listed in Table 1). Focusing on the Lopinavir/Ritonavir,
both are heterocyclic compounds with the liver a major site for
Lopinavirmetabolism. After uptake Lopinavir is released into circulation
wheremost of it binds to plasma proteins (N97%) [16] whereafter it can
be taken up, to varying degrees, by most tissues including the heart
(based on study in animal model) [16]. Lopinavir is metabolized to a
number of oxidative metabolites, although the parent compound is
the major circulating drug with only a small percentage of metabolites
present [16,17]. Such metabolites are also less potent inhibitors of the
HIV protease [18]. Since Lopinavir is metabolized by the hepatic cyto-
chrome P450 (CYP) enzymes CYP3A4 and CYP3A5 [17], its circulating
concentrations are inadequate to suppress viral replication (if employed
as monotherapy). However, Ritonavir potently inhibits CYP3A4 and
CYP3A5, thereby ensuring higher Lopinavir plasma concentrations
[19,20]. In light of this, Ritonavir was co-formulated with Lopinavir,
i.e. Kaletra™ and Aluvia™ (the latter with improved heat stability) [19].
HIV PIs are implicated in the development of cardiovascular compli-
cations with greater risk for acute myocardial infarction (AMI) and cor-
onary syndromes. One of the largest clinical studies assessing the risk
for AMI with HAART—the Data Collection for Adverse events of Anti-
HIV Drugs (DAD) Study Group—recruited 23, 468 HIV-positive patients
on ART [21–23] and established that cumulative HAART exposure was
linked to a robust increase for AMI (26% relative change). Here the
HIV PIs contributed the most signiﬁcant risk to AMI onset. Although
the absolute risk for AMI was low when adjusted for confounding pa-
rameters, HAART and PIs exacerbated traditional CVD risk factors such
as cholesterol, lipid abnormalities, and diabetes. Similar results werembrane of the host cell; 2. Single-strand viral RNA enters the host nucleus; 3. Viral reverse
nters the nucleus and integrates itself within the host's DNA with integrase; 6. The host's
multi-protein complexes assemble and bud at the host's cell wall where proteases cleave
f the viral life cycle—fusion inhibitors, reverse transcriptase (RTI), nucleosides and non-
ibitors (PI). HIV—human immunodeﬁciency virus.
Table 1
HIV protease inhibitors and associated complications.
Name Trade name Manufacturer Side Effects
Indinavir Crixivan Merck & Co. ER stress [129,131], mitochondrial toxicity [113], inhibition of GLUT4 [207]
Nelﬁnavir Viracept Agouron Pharmaceuticals ↑UCP3, IR, ↑ROS [93,95]
Lopinavir/Ritonavir Kaletra Abbott Hyperlipidemia, LD, dyslipidemia, MetS, CVD, IR, DM [21,22,131], ER stress [53,141–143],
↑ROS, ECG abnormalities [182,183]
Atazanavir Reyataz Bristol-Myers Squibb ECG abnormalities [182,183], Crystalluria [208]
Darunavir Prezista Tibotec Crystalluria [208]
Saquinavir Invirase/Fortovase Hoffman-La/Roche Alterations to mitochondrial metabolism, ER stress [209]
Amprenavir Agernerase GlaxoSmithKline Dyslipidemia [210]
Fosamprenavir Lexiva/Telzir GlaxoSmithKline ↑ Liver enzymes [211]
Tipranavir Aptivus Boehringer-Ingelheim Mild hepatic side-effects [212]
Symbols: ↑—increase. Abbreviations: CVD—cardiovascular diseases, DM—diabetes mellitus, ER—endoplasmic reticulum, ECG—electrocardiogram, GLUT4—glucose transporter 4, IR—
insulin resistance, LD—lipodystrophy, MetS—metabolic syndrome, ROS—reactive oxygen species.
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remained low [24,25] but with PIs signiﬁcantly associated with AMI
occurrence [21,22,24–29]. Moreover, cumulative exposure to HAART
regimens (including PIs) can increasemortality [5,23,30,31] andhospital-
ization for cardiovascular complications [32] in the long-term. Echocar-
diographic abnormalities are also associated with the use of Ritonavir,
e.g. baseline echocardiography showed signiﬁcant left ventricular systolic
and diastolic dysfunction, pulmonary hypertension, and left atrial en-
largement in an HIV-infected cohort [33]. Although some studies do not
support a connection between PIs and atherosclerosis [27,34] (due to
minimal differences found between PIs and other ARVs in HAART),
many others do report a clear link with the development of subclinical
atherosclerotic lesions [35–38] and thrombotic environments [39,40]
(Table 2). Together these data implicate HIV PIs in the development of
CVD in HIV-positive patients, although this may vary depending on the
particular drug cocktail employed and also the duration of treatment.
As highlighted earlier, HIV PIs exert direct and indirect effects (e.g. al-
tered metabolism—systemic and organ-related) on the cardiovascular
system. Although the focus of this article is largely on direct effects, it is
important to also brieﬂy review the indirect outcomes of HIV PIs since
this will help provide a more complete picture of this complexTable 2
PI treatment and the risk for MI and cardiovascular complications (clinical studies).
Author (s) No. Participants Status
Friis–Møller N [21,22]
Smith C [23] 
23, 000 
to 33, 000
HIV+
Holmberg SD [24] 5672 HIV+
Mary–Krause M [25] 34, 976 HIV+
Durand M [26] 7, 053
27, 681
HIV+
HIV–
Lang S [28] 289
884
HIV+
HIV–
Coplan PM [29] 10, 986 HIV+
Triant VA [30] 3, 851
1, 044 589
HIV+
HIV–
Klein D [32] 4, 159
39, 877
HIV+
HIV–
Lifson AR [31] 1, 600 HIV+
Mondy KE [33] 656 HIV+
Sullivan PS [27] 42, 935 HIV+
Lyonne L [34] 780 HIV+
Maggi P [35] 293 HIV+
Bernal E [36] 152 HIV+
de Saint Martin L [37] 154 HIV+
Jerico C [38] 132 HIV+
Symbols: ↑—increase. Abbreviations: AMI—acute myocardial infarction, CVD—cardiovascular
infarction, NI—not indicated, PI—protease inhibitor.phenomenon. Here PIs can trigger metabolic side-effects that resemble
the metabolic syndrome, a combination of risk factors that predispose
to future onset of type 2 diabetes mellitus and CVD [41]. Various deﬁni-
tions and cut-off parameters exist for the metabolic syndrome but the
main risk factors include abdominal obesity, atherogenic dyslipidemia,
insulin resistance (with or without glucose intolerance), elevated blood
pressure, pro-inﬂammatory status and a pro-thrombotic state [41–43].
In support, human- [44–50], animal- [51–53] and cell-based [54–57]
studies demonstrate that increased plasma cholesterol and triglyceride
levels, and the development of lipodystrophy and insulin resistance, are
the most commonmetabolic perturbations found with HIV PI treatment.
With PI-mediated lipodystrophy, an imbalance in fat partitioning oc-
curswith lipoatrophy occurring at the extremities (e.g. lower legs, arms,
face) and central accumulation of fatty tissue especially at subcutaneous
sites (e.g. waist, hips, neck). The over-accumulation of subcutaneous fat
elevates cholesterol and triglyceride levels within the abdominal area,
thereby causing dyslipidemia. Furthermore, increased lipodystrophy
with HIV infection can change fatty acid metabolism. For example,
Sekhar et al. (2002) [58] established that HIV-positive men with
lipodystrophy displayed higher resting energy expenditure rates, ele-
vated free fatty acids and fatty acid oxidation rates compared to healthyPI use? Outcome(s)
Yes
PIs ↑ AMI events, associated with MI 
risk, and ↑ risk for CVD
Yes
Yes
Yes
No
Yes
No
Yes
Yes
No
PIs ↑ mortality and/or hospitalization 
due to cardiova scular complications
Yes
No
NI
Yes ECG abnormalities with PI use
Yes Minimal link with PIs and 
atherosclerotic lesionsYes
Yes
PIs associated with subclinical 
atherosclerotic lesions
Yes
Yes
NI
diseases, ECG—electrocardiogram, HIV—human immunodeﬁciency virus, MI—myocardial
Table 3
Lipid changes associated with PI therapy (clinical studies).
Author(s) No.
Participants
Status PI
use?
Outcome(s)
38
17
HIV+
HIV-
Yes
No
 plasma cholesterol,  triglycerides, LD and IR
development with PIs
Bastard J [45] 26
18
HIV+
HIV-
Yes
No
Carr A [46] 81 HIV+ Yes
Dong K [47] 42 HIV+ NI
Gan S [48] 10
10
HIV+
HIV+
Yes
No
221 HIV+ Yes
125 HIV+ Yes
Sekhar R [58] 6
6
HIV+
HIV-
Yes
No
LD,  REE,  FAO,  FFA
41 HIV+ Yes
Anthropometric changes accompanied with 
development of dyslipidemia and MetS with PI
treatment ≥ 12 months
Bernal E [36] 152 HIV+ Yes
[60] 148
47
[61] 140
[67] 113
45
HIV+
HIV-
HIV+
HIV+
HIV+
Yes
No
Yes
Yes
No
287
287
HIV+
HIV-
NI
Biron A [63] 269 HIV+ Yes
Floris-Moore
M [50]
Tsiodras S
[49]
Behrens G
[44]
Mulligan K
[59]
Carr A
[60,61,67]
Gazzaruso C
[62]
Symbols: ↑—increase. Abbreviations: FAO—fatty acid oxidation, FFA—free fatty acids, IR—
insulin resistance, LD—lipodystrophy, MetS—metabolic syndrome, PI—protease inhibitor,
REE—resting energy expenditure.
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dividuals were highly indicative of the metabolic syndrome. Studies
evaluating anthropometric changes established that PI-mediated meta-
bolic derangements may occur before the onset of overt body changes
such as increased waist circumference and weight gain [59]. However,
dyslipidemia and the metabolic syndrome can also manifest simulta-
neously with anthropometric alterations, especially for HIV PI therapy
lasting longer than 12 months [36,60–64]. Table 3 summarizes the
main clinical ﬁndings relating to alterations in lipid metabolism with
PIs. HIV PIs can also trigger alterations to glucose metabolism, e.g. it
can impair glucose tolerance as well as whole-body glucose disposal,
glucose uptake, transport and phosphorylation and cause insulin resis-
tance at peripheral sites such as skeletal muscle [44,65,66].
Together such metabolic derangements can trigger inﬂammation,
stress the myocardium [67,68], and may potentially predict the onset
of insulin resistance and cardiac dysfunction [48,69]. These data indicate
that HIV PIs have far-reaching consequences on metabolism that may
eventually impact on cardiovascular function. How does this occur? It
is likely that PIs act early-on at the molecular level to activate key met-
abolic pathways, and initiate a cascade of detrimental alterations that
progressively contribute to the development and presentation of dyslip-
idemia, lipodystrophy and weight gain (some of these aspects will be
discussed in Section 4.2.3 of this article).
4. Molecular mechanisms underlying PI-mediated cardio-metabolic
perturbations: spotlight on oxidative stress and the UPS
There are several mechanisms whereby HIV-PIs can exert its detri-
mental effects on the heart, however, we propose that PI-induced gen-
eration of oxidative stress and UPS dysregulation, and associated
downstream targets, play a central role in this process.
4.1. Reactive oxygen species (ROS)
4.1.1. The basics
The main intracellular sources of ROS production include the mito-
chondrial electron transport chain (ETC) [70,71], NADPH oxidases
(NOX) [72,73], xanthine oxidase [74,75], and cytochrome P450 [76,77].
However, the majority of ROS production originates from mitochondria,generated by respiratory chain complexes I and III located within the
innermitochondrialmembrane [78]. Additional sources ofmitochondrial
ROS include matrix dehydrogenases and mono-amine oxidase found in
the outer mitochondrial membrane (reviewed in [79]). Electrons leaking
frommitochondrial respiratory complexes I and III can bind tomolecular
oxygen to form superoxide (O2•−). Intriguingly, these complexes gener-
ate two distinct O2•− pools. Complex I releases O2•− from the innermito-
chondrial membrane (impermeable to superoxide) into the matrix
[71,78]. Superoxide found within the mitochondrial matrix can be con-
verted to hydrogen peroxide (H2O2) by manganese superoxide dismut-
ase (MnSOD), i.e. 2O2•− + 2H+ → O2 + H2O2. However, complex III
can release O2•− into both the mitochondrial matrix and the inter-
mitochondrialmembrane space, and since the outermitochondrialmem-
brane is permeable toO2•− it can translocate into the cytosol. Copper/zinc
SOD (Cu/ZnSOD) converts O2•− to H2O2within the cytosol and the inter-
mitochondrial membrane space. Thereafter H2O2 can be removed by cat-
alase or glutathione peroxidase [80,81]. However, in the mitochondrial
matrix glutathione peroxidase is themain regulator of H2O2with catalase
playing an insigniﬁcant role [82].
Physiologic ROS levels play a crucial role in regulating intracellular
signaling pathways and gene expression, referred to as “redox signaling”
[83,84]. Here NOXs are key modulators that generate highly regulated
amounts of O2•− by electron transfer from NADPH to molecular oxygen
[85–88]. However, excess and damaging reactive speciesmaybe generat-
ed by increased activation of reactive species-generating systems and/or
decreased capacity of antioxidant defense systems. For example, if O2•−
and H2O2 are not appropriately detoxiﬁed then H2O2 can be converted
to the highly reactive hydroxyl anion (OH•) by non-enzymatic pathways,
e.g. the Fenton reaction [89] while O2•− can react with nitric oxide to
form peroxynitrite (ONOO−) [89].
4.1.2. The link between HIV PIs and oxidative stress
The link between HIV-PI usage and increased ROS production is well
established by several human [90], animal [91–94] and cell-based studies
[95–99]. These include numerous cell and tissue types, i.e. macrophages
[97], cardiomyocytes [100], endothelial cells [101,102], pancreatic β-
cells [91,93], intestinal epithelial cells [103], pulmonary aortic endothelial
cells [104], human skeletal muscle cells [94], adipocytes [95,105], hippo-
campal neurons [106], porcine arteries [98,107], and aortas in an athero-
genic mouse model [98,101,107]. What are the origins of PI-induced
ROS? The precise source(s) of PI-induced ROS remain unclear although
most studies suggest a mitochondrial origin [99]. However, Ritonavir
treatment of porcine carotid arteries increased O2•− production by NOX
indicating the presence of extra-mitochondrial ROS [98].
The exact mechanisms and sequence of events whereby PI treatment
triggers intracellular ROS production are not well understood. In light of
this we propose a uniﬁed model based on the current literature that fea-
tures a wide variety of experimental models and cell types (Fig. 2). Of
note, there is limited information of PI-mediated effects on the intact
heart and further studies are required to ascertain whether this model
applies to the mammalian heart. In the ﬁrst instance we propose that
PIs exert acute anddirect effects on enzymes that regulate the balance be-
tween ROS generation and detoxiﬁcation. For example, the PI Nelﬁnavir
decreased intracellular Cu/ZnSOD (but not MnSOD) activity, thereby ele-
vating cytosolic ROS generation in rat pancreatic cells [93]. In agreement,
glutathione levels were attenuated suggesting decreased glutathione
peroxidase activity, although this was not determined. Diminished Cu/
ZnSOD and glutathione peroxidase activities will be expected to increase
ROS levels within the cytosol and the inter-mitochondrial membrane
space. Cytosolic ROS levels may be further enhanced by leakage of reac-
tive species across the porous outer mitochondrial membrane. We fur-
ther propose that intracellular ROS generated in this way (cytosolic and
inter-membrane space) are able to inhibit respiratory chain complexes
located within the inner mitochondrial membrane (reviewed in [108]).
Thus a vicious cycle is created whereby decreased ETC activity will
generate more reactive species thereby further elevating intracellular
Fig. 2.HIV-PIs and oxidative stress. HIV PIs elicit a variety of effects at the cellular level. For example, PIs increase NADPH oxidase, and decrease Cu/ZnSOD and COX4 gene expression.
This would be expected to increase and decrease NADPH oxidase and Cu/ZnSOD activities, respectively. Moreover, lower COX4 levels may impair mitochondrial respiratory capacity.
PIs can also directly affect enzyme activities of Cu/Zn SOD and NADPH oxidase in the cytosol, resulting in ROS generationwith damaging intracellular effects. Mitochondrial Cu/ZnSOD
activity is also downregulated and thus increases the generation of ROSwithin the intermembrane space. Higher ROS levelsmay inhibit complexes I and III of the ETC, thereby increas-
ingmatrix and cytosolic ROS levels. In thismanner, mitochondria are also damaged.O2•− superoxide free radical, OH•—hydroxyl radical, H2O2—hydrogen peroxide, ONOO−—peroxynitrite,
Cu/Zn SOD—copper/zinc superoxide dismutase, COX4: cytochrome c oxidase 4, NADPH—Nicotinamide adenine dinucleotide phosphate hydrogen, PI—protease inhibitor, ROS: reactive oxygen
species.
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ide production from complex I will enhance mitochondrial ROS levels
(conﬁned within the matrix) with detrimental effects. PI-induced
increases in NOX activity will further exacerbate these effects by gen-
erating even higher O2•− levels. We believe that it is unlikely that PIs
directly inhibit the respiratory chain complexes since there is no
evidence, as far as we are aware, supporting PI localization within
the mitochondrial matrix. In agreement, Vernochet et al. (2005)
[109] tracked intracellular localization of PIs by ﬂuorescent tagging
and found no localization within the nucleus. They did not report on
the mitochondrial localization of PIs, but its lack within the nucleus
suggests it is unlikely that it entered themitochondrialmatrix. Howev-
er, further studies are required to ascertain whether PIs are able to
enter thematrix and exert direct effects onmyocardial ETC complexes.
At another level, PIsmay also exert longer-term transcriptional effects
thereby altering expression of ROS generating/detoxifying enzymes and
increasing intracellular reactive species levels. For example, Ritonavir-
treated cells exhibited elevated mRNA levels of NOX subunits p22phox,
p40phox, p47phox, and p67phox [97]. NOX is a multi-subunit complex and
its enzymatic activity depends on both catalytic and regulatory subunits
(e.g. p22, p40, p47, and p67) [77]. Ritonavir treatment also increased
O2•− levels, thus suggesting higher NOX activity. Investigation of the
NOX pathway further supports the role of PIs in oxidative stress. In addi-
tion, Chai et al. (2010) [110] investigated PI treatment in porcine coronary
arteries and found decreased endothelial nitric oxide synthase expression
with Ritonavir therapy, together with increased nitric oxide levels. Func-
tional studies established decreased endothelium-dependent vasorelax-
ation thus conﬁrming these ﬁndings [96,98,99,107,111]. Of note, HIV
infection itself also plays a role in altering intracellular oxidant status, i.e.
a transgenic rodentmodel expressing HIV proteins Tat, gp120 andNef re-
vealed detrimental perturbations in the cysteine and glutathione path-
ways with additional changes to cardiacmorphological parameters [112].HIV PI treatment can also attenuate expression of antioxidant mod-
ulators. For example, Nelﬁnavir decreased Cu/ZnSOD, but not MnSOD,
peptide levels in rat pancreatic β-cells, associated with greater enzyme
activity and higher ROS production [93]. These data suggest that PIs
more likely exert transcriptional effects on nuclear-encoded compared
to mitochondrial-encoded DNA. However, adipocytes exposed to PIs
displayed reduced gene expression of both nuclear-encoded cyto-
chrome c oxidase-4 (COX4), and mitochondrial-encoded COX2 [113].
Decreased COX levels may impair complex IV capacity (i.e. accepting
electrons to reduce molecular oxygen to water), increase electron leak-
age within ETC complexes and thereby elevate O2•− production.
We therefore propose that PI-mediated ROSgenerationmayoccur in
an acute and/or chronicmanner, that in turn is dependent on the length
and type of HIV-PI treatment. For example, we found no evidence of
damaging effects of myocardial oxidative stress in rats exposed to
Lopinavir/Ritonavir for 8 weeks [114,115]. However, PI-treated hearts
exhibited augmentedmyocardial SOD activity (cytosolic andmitochon-
drial) suggesting that intracellular defense systems are initially effective
in blunting such PI-mediated effects. Thus our ﬁndings suggest that HIV
PI-mediated chronic, transcriptional changes likely trump acute effects
elicited by such treatment (i.e. short-term increases in ROS production).
However, we are of the opinion that this relationship is likely to vary de-
pending on the type and dose of HIV PI employed, experimental model
used, as well as the duration of drug administration. Further studies are
required to shed light on this interesting question. Together these ﬁnd-
ings imply that this adaptive response may be overwhelmedwith long-
term HIV-PI treatment, resulting in signiﬁcantly higher ROS production
with detrimental consequences (Fig. 2).
Thus PI treatment can increase ROS thereby causing damaging effects.
For example, excitation–contraction coupling can become disrupted
under these conditions resulting in detrimental consequences for cardiac
myoﬁber physiology, and also endoplasmic reticulum (ER) stress. The
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(SERCA), and sodium–calcium exchanger (NCX) all possess sulfhydryl
(SH) groups of cysteine residues that can be modiﬁed by oxidation/
reduction. Here the RyR SH-groups are reduced to thiols thereby keeping
the channel open [116–119], while the SERCA-2a [120–125] andNCX SH-
groups [126–128] are oxidized rendering it inactive and unable to pump
cytosolic calcium back into the sarcoplasmic reticulum. The consequence
is calcium overload that leads to damaging downstream effects at both
the mitochondrial (e.g. decreased respiratory capacity and energy pro-
duction, and greater activation of cell death pathways) and contractile
levels; namely, a further exacerbation of ionic imbalance and toxicity,
redox status of the myocardium, while excess ROS can inhibit calcium-
ATP-hydrolysis coupling [120]. The depletion of endoplasmic calcium
stores can also trigger ER stress thatmay result in the accumulation of un-
folded proteins and ER-induced apoptosis (reviewed in [129]).
In fact, ER stress is proposed to be an additional commonmechanism
for PI-induced side-effects such as oxidative stress and altered lipid me-
tabolism. The ER works closely together with the proteasome and the
unfolding protein response (UPR) to ensure protein synthesis, folding,
transport and degradation. Disruptions to ER signaling lead to an accu-
mulation of misfolded proteins and ER stress, that were previously
linked to the development of lipid accumulation, oxidative stress, IR
and T2DM [104,130–136]. Importantly, PIs can exacerbate ER stress
with negative downstream consequences. For example, cultured and
primary mouse, and human adipocytes treated with clinically relevant
doses of PIs (including Lopinavir/Ritonavir) showed signiﬁcant activa-
tion of the ER stress response and it was linked to inhibition of autoph-
agy (most likely through inhibition of the proteasome) with C/EBP
homologous protein (CHOP) as themajor transcriptional factor regulat-
ing this process [137]. Autophagy itself is an important regulator of he-
patic lipid metabolism and adipocyte lipid storage, and thus PI-induced
disruptionmay result in dyslipidemia [138–140]. Others also found that
PI therapy can induce ER stress-related genes and its activation
[53,141,142]. Furthermore, microarray analysis of adipocytes treated
with Ritonavir revealed amarked elevation in expression of genes asso-
ciatedwith inﬂammation, oxidative stress, ER stress and apoptosis [143].
Alterations in calcium signaling, oxidative stress and direct inhibition of
the UPSmay therefore initiate and aggravate the ER stress response. Fur-
ther downstream effects include disruption of lipid homeostasis at key
metabolic tissues (liver, adipose), activation of intracellular death path-
ways and increasing the pro-oxidative status of the intracellular environ-
ment. Ultimately, this would feed into the more indirect PI-mediated
effects, i.e. create an atherogenic, pro-oxidative environment and in-
crease the risk for future cardio-metabolic complications.
ROS-mediated changesmay alsomanifest at themitochondrial level
(reviewed in [144]). For example, PIs can increase mitochondrial mem-
brane potential depolarization in HL-1 myocytes [100] that would be
expected to impair mitochondrial respiration and ATP generating ca-
pacity. In agreement, others found higher mitochondrial membrane
depolarization together with an impairment of cellular oxygen con-
sumption [145]. We are of the opinion that activation of uncoupling
proteins (UCP) may help mediate such effects, e.g. Nelﬁnavir treatment
elevated UCP2 levels in pancreatic β-cells [93]. Impairment of mito-
chondrial function may also result to due mitochondrial DNA damage
and fragmentation of the mitochondrial network [146,147].
Together we propose that oxidative stress-induced changes play a
central role in damaging effects (e.g. endothelial dysfunction and in-
creased susceptibility to AMI) triggered by long-term HIV PI treatment.
This may provide a useful opportunity to consider appropriate co-
treatments, e.g. the deleterious effects of PI exposure in primary human
skeletalmyotubes (elevated ROS, ER stress)were inhibited by the antiox-
idant resveratrol [94]. However, most studies performed in this research
niche area were done within the in vitro context and largely on non-
cardiac cell lines, therefore necessitating further research work on the
heart by employing multiple modes of investigation (cell-, animal-, and
clinical-based studies).4.2. The UPS: a downstream target of oxidative stress?
There are several targets that can potentially link PI-induced ROS
production to cardiac pathophysiology. However, we will here focus
on dysregulation of the UPS since it is our opinion that it represents a
key downstream mediator of HIV PIs that fuels the onset of impaired
cardiac contractile function.
4.2.1. The ABCs of the UPS
The UPS is an important regulatory system that monitors protein
quality especially in cardiac cells where such control is vital due to the
high rate of protein turnover, energy requirements and physical stress
that can occur [148–150]. Ubiquitination occurs by three enzymes that
require ubiquitin (E1), conjugation of ubiquitin (E2) and attachment
via ligase (E3) enzymes (ATP-dependent reactions). The 26S protea-
some is amulti-catalytic,multi-unit complex consisting of a 20S proteo-
lytic core capped at each end by 19S components (Fig. 3A). The 20S
catalytic subunit degrades proteins via its chymotrypsin-, trypsin- and
caspase-like activities (ATP-independent process).
Mitochondrial proteins make up a fair proportion of overall
ubiquitinated proteins and most ETC complexes, e.g. F1F0-ATPase sub-
units, ﬂavoproteins, and NADH-ubiquinones, possess ubiquitin binding
sites and therefore act as ubiquitin substrates [151]. The rationale is ap-
parent since themitochondrion is the powerhouse for energymetabolism
therefore necessitating in-housemechanisms to ensure adequate protein
quality control. Mitochondria contain ubiquitin activating enzymes (E1)
and E3 ligases found within the outer mitochondrial membrane
[152–154]. However, the proteasome is not present withinmitochon-
dria thus raising the question howmitochondrial proteins are actual-
ly ubiquitinated and degraded by this system. Here mitochondrial-
associated degradation plays a role, i.e. mitochondrial E1 tag proteins
for ubiquitination, with subsequent retro-translocation to the outer mi-
tochondrial membrane and further ubiquitination by E3 ligases
[155–159]. Emerging data support this notion, i.e. the F1F0-ATPase re-
siding at the inner mitochondrial membrane can be retro-translocated
to the outer mitochondrial membrane, ubiquitinated and subjected to
proteolysis [160]. The UPS also regulate numerous other (non-mito-
chondrial) classes of proteins that include key contractile regulators
(e.g. SERCA2 and desmin), cardiac ion transporters and several tran-
scriptional modulators [151].
4.2.2. HIV PIs and dysregulation of the UPS
Dysregulation of the UPS can elicit maladaptive effects, e.g. certain
conditions such as Parkinson's disease are associated with the accumula-
tion of ubiquitinated proteins and defective degradation [161]. The ques-
tion therefore arises whether HIV PIs actually perturb myocardial UPS
functioning within the heart and how precisely this occurs. It is our
view that PIs can impair cardiac UPS activity directly (Fig. 3B) and thereby
triggering oxidative stress. The UPS forms an important part of the cell's
antioxidant defenses bymanaging protein degradation in response to ox-
idative stress. The intracellular redox status has a signiﬁcant impact on
UPS function, with the 26S proteasome particularly sensitive to its oxida-
tive environment [162,163]. This will of course be particularly relevant
within the context ofHIVPI-mediated inductionof oxidative stress.More-
over, lipid peroxidation can also blunt cardiac 20S proteasome activity
[162,163] while ubiquitin activating and conjugating enzymes can be
inhibited by oxidative stress (reviewed in [164]. Oxidatively modiﬁed
proteins are known substrates for ubiquitination[165,166] and im-
proper removal may increase the overall intracellular oxidant burden.
Together these studies show that oxidative stress can inhibit UPS ac-
tivity and increase the generation of free radicals [161,166–168]. This
in turn places greater oxidative stress on the cell and antioxidant sys-
tems, andmay create a vicious cycle of perpetual inhibition of proteol-
ysis and accumulation of ubiquitin aggregates.
HIV PIs can also trigger direct effects on the UPS. For example, we
recently employed a rat experimental model to evaluate the effects of
Fig. 3. The ubiquitin–proteasome system (UPS). (A) The UPS is sequentially activated by three key enzymes. 1) E1 activates and prepares ubiquitin; 2) E1 associateswith ubiquitin to form
a complex; 3) The conjugating enzyme E2 associates with the E1–Ub complex; 4) The conjugation of the Ubmoiety and E3 on the target protein, which then binds to the multi-catalytic
proteasome; 5) The proteasomal activities of the various subunits ensure that the target protein is degraded; and. 6) Ub dissociates from the complex and peptides are released into the
cytosol for further processing. (B) PIs competitively bind to and inhibit proteasomal subunits, thereby decreasing its ability to degrade and recycle target proteins, resulting in an accumu-
lation of ubiquitinated proteins within the cell. 19S and 20S—proteasomal subunits, PI—protease inhibitor, Ub—ubiquitin.
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demonstrated that Lopinavir/Ritonavir exposure signiﬁcantly lowered
myocardial chymotrypsin-like and caspase-like, but not trypsin-like
proteasomal activities, while heart function was impaired at physiologi-
cally relevant concentrations [115]. In parallel, global ubiquitination
of total proteins signiﬁcantly increased. However, myocardial oxida-
tive stress in our model was not signiﬁcantly increased, suggesting
that in this instance Lopinavir/Ritonavir exerted direct effects on
the cardiac UPS. In support, others found that PI Ritonavir attenuated
chymotrypsin- and trypsin-like activities of the 20S UPS subunit in
hepatocytes [169] at multiple concentrations (physiologically rele-
vant and higher), while microarray analyses revealed that rats acute-
ly treated with Ritonavir displayed a marked increase in gene and
protein content for proteasomal components [170]. Together these
studies show that HIV PIs can competitively bind to and inhibit
proteasomal subunits, thereby decreasing its ability to degrade and
recycle target proteins (Fig. 3B). This results in an accumulation of
ubiquitinated proteins within the cell, with damaging outcomes that
can help explain both the direct and indirect effects of HIV PIs on cardiac
function.4.2.3. Dysregulation of the UPS and transcriptional effects—explanation for
indirect effects of HIV PIs?
We propose that PI-mediated impairment of the UPS may also help
explain secondary outcomes of HIV PIs, i.e. the induction of metabolic
dysfunction that subsequently predisposes to the onset of CVD. What
UPS-regulated proteins are likely to play key roles in this instance? The
HIV-PIs can exert unfavorable effects at the gene transcriptional level,
e.g. by activating sterol regulatory element binding protein (SREBP)
[171], a key lipid transcriptional modulator expressed inmajormetabolic
tissues [172]. Upon activation, SREBP binds to sterol-regulatory-element
(SRE)-containing promoter sequences in several lipogenic and
cholesterogenic genes that ultimately results in the production of choles-
terol (high and low density lipoproteins) and sterol components [173].
Since SREBPs are ubiquitinated and degraded by the UPS [174,175]
this raises the possibility that inhibition of this system may contribute
to development of dyslipidemia in HIV-infected individuals treated with
PIs.When the UPS is inhibited, levels of ubiquitinated SREBPs increase to-
gether with the subsequent activation of target lipid genes [175]. The
ubiquitination of SREBP-1 occurswhile it is bound to the promoter region
of its target gene. Here the E3 ligase Fbw7 associates with bound SREBP-1
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thereby halting transcription of the target gene(s) [174]. Thus SREBP
levels are controlled by DNA binding, and UPS inhibition effectively
means SREBPs remain bound to DNA promoters for longer.
Higher nuclear SREBP levels would increase gene expression of tar-
get genes and help explain a number of in vitro [176,177] and in vivo
[171,177–179] studies demonstrating that HIV PIs can exert lipid-
related perturbations at the transcriptional level. For example, genes
regulating hepatic fatty acid synthesis and oxidation were up- and
down-regulated, respectively, following seven days of PI administration
to rats [178]. Furthermore, a Western-style diet administered together
with Ritonavir (for 14 days) resulted in the exacerbation of the hyper-
lipidemic phenotype, hepatic steatosis and hepatomegaly [171] with
hepatic accumulation of SREBP. Our research reveals similar ﬁndings,
i.e. Lopinavir/Ritonavir treatment induced hepatic gene expression of
acetyl-CoA carboxylase-beta (accβ) and 3-hydroxy-3-methyl-glutaryl-
CoA reductase (hmg-cr) (SREBP target genes) that would be expected
to enhance fatty acid oxidation and cholesterol synthesis, respectively.
Moreover, expression of mitochondrial glycerol-3-phosphate acyltrans-
ferase (marker of glycero-lipid synthesis) was robustly upregulated in
adipose tissue of treated rats. We propose that this could help explain
the higher serum LDL-cholesterol levels found i.e. via greater adipose
triglyceride synthesis and subsequent export to the liver. Here increased
hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase expression may
enhance VLDL production and with a corresponding elevation in the
availability of circulating LDL-cholesterol.
Together this shows how the indirect effects of HIV PIs can occur, i.e.
altering lipidmetabolismbyUPS inhibition and the subsequent activation
of the SREBP transcriptional pathway to enhance expression of key
lipogenic and cholesterogenic enzymes. This in turn will eventually lead
to an increased risk for future atherosclerotic and cardiovascular compli-
cations. Further evidence show that HIV-1 itself can directly interact with
the proteasome and decrease the host's immune response [180,181]. Of
note, the viral infectivity factor (Vif) of HIV targets the cytidine deaminase
APOBEC3 protein for ubiquitination and subsequent degradation, hinder-
ing C-to-U mutations within the viral DNA to inhibit viral replication
[181]. This indicates that both the virus and HIV PIs can deal a “double
blow” to UPS functioning thatmay have serious long-term consequences.
4.2.4. Dysregulation of the UPS and link to perturbed ionic function and
electrical signaling with HIV PI exposure—explanation for direct effects of
HIV PIs on the heart?
Clinical studies show that PI treatment can trigger electrical signaling
irregularities, i.e. prolonged PR duration and QRS interval in HIV-positive
patients [182,183], and PIs emerged as independent predictors of in-
creased PR durations and ECG abnormalities [183]. Similar research is in
agreement with these ﬁndings [184–187], albeit inconsistently
[188,189]. Mechanistic studies demonstrate that HIV PIs can have far-
reaching consequences on myocardial ionic and electrical homeostasis.
For example, PI-mediated alterations in calciummetabolismwere discov-
ered in human [182,183] and cell-based studies [100]. Deng et al. (2010)
[100] established that HL-1 cardiomyocytes exposed to Lopinavir and Ri-
tonavir, respectively, displayed activation of the volume-sensitive chlo-
ride ion channel, important during the stress response (swelling) and
mechanical force (stretching). Here the action potential durationwas sig-
niﬁcantly shortenedbyRitonavir exposure, togetherwith depolarizedmi-
tochondrial membrane potential and higher mitochondrial ROS levels.
Thus if ion channels become dysfunctional, action potential propagation
occurs sub-optimally thereby leading to an ionic imbalance and leakage
of critical ions (e.g. calcium, sodium, potassium) into cellular compart-
ments and upsetting the electrical gradient across membranes. This can
further manifest as disjointed electrical signaling between the SA node,
His and Purkinje ﬁbers locatedwithin the atria and the ventricles, respec-
tively. Disturbed impulse propagation between cardiomyocytes is also
implicated in negative outcomes elicited by HIV PI treatment. Here junc-
tions—necessary to transfer electrical signals and chemical messengersbetween adjacent myocytes—are formed from two hemi-channels
(connexons) [190]. When two neighboring gap junctions connect then
it becomes connexins that are differentially distributed within the myo-
cardium. Connexin 43 the most abundant [191–195] in the heart, and al-
tered expression levelsmay precede the onset of arrhythmias, ventricular
ﬁbrillation and incorrect signal propagation in the long-term [196–201].
The question arises whether dysregulated UPS is linked to any of the
PI-mediated ionic and electrical disturbances discussed. Since the protein
turnover of connexin 43 is regulated by the UPS [151,202–205], we pro-
pose that may help explain perturbed expression documented with HIV
PI exposure. In agreement, our laboratory found elevated connexin 43 ex-
pression together with blunted UPS function in rat hearts exposed to
Lopinavir/Ritonavir. In parallel, myocardial calcineurin levelswere upreg-
ulated [114,115]. However, connexin 43may also be a downstream target
of calcineurin, i.e. cardiac-speciﬁc calcineurin overexpression diminished
phosphorylation and redistribution of connexin 43 that was associated
with depressed contractility and cardiac hypertrophy [206]. The proposal
is made that attenuated expression levels may be linked to altered gap
junction assembly and arrythmogenesis [206]. Together theseﬁndings in-
dicate that PI-mediated changes in myocardial connexin 43 expression
may compromise gap junction function and electrical signaling, leading
to impaired contractile function. However, further investigations are
needed to evaluate this interesting question in the heart and whether
PI-induced UPS maladaptation and/or altered calcineurin activation are
indeed responsible for connexin 43 dysregulation in this instance.
5. Summary and conclusion
In summary, this review article aimed to shed light on potential
mechanisms whereby long-term PI treatment can result in cardio-
metabolic dysfunction in HIV-positive individuals. Based on the literature
reviewed we propose a unifying hypothesis that revolves around central
role played by PI-mediated oxidative stress and dysregulation of the UPS
in this instance (Fig. 4). Themodel largely focuses on direct effects medi-
ated by HIV PIs, but also attempts to explain how altered UPS function
may provide insight regarding indirect, metabolic effects that can also re-
sult fromsuch treatment. Higher intracellular ROSproduction signiﬁcant-
ly impacts on cell death, mitochondrial respiration and energy
production. Here elevated oxidative stress is known to initiate apoptosis,
a likely common outcome for ROS-induced ER stress. Attenuated respira-
tory capacity may occur via direct oxidation of mitochondrial ETC com-
plexes, and by damaged mtDNA leading to decreased expression of
proteins required for optimal mitochondrial ATP production. We further
propose that increased ROS-mediated activation of UCPs can result in
greater depolarization of the inner mitochondrial membrane and result
in diminished mitochondrial ATP production. Since a constant energy
supply is vital for optimal contractile function, lower ATP availability
will have serious consequences for the heart's function.
The UPS is also a downstream target of ROS, although there is cross-
talk between these two systems. Moreover, we propose that HIV PIs
may impair UPS in the heart and elicit direct and indirect effects. Subse-
quently, this is accompanied by enhanced transcription (largely SREBP-
mediated) of target genes for cholesterol and lipidmetabolism that con-
tributes to the establishment of a pro-atherogenic setting. We propose
that this may—in part—also help explain some of the indirect, metabolic
effects of HIV PIs. Dysfunctional UPSmay also trigger alterations in ionic
channels and interfere with electrical signaling in the myocardium.
Thus our model implicates both direct (ionic channels, electrical signal-
ing) and indirect (pro-atherogenic milieu) mechanisms whereby PIs
eventually lead to the development of heart diseases. Thus while PIs
substantially improve life expectancy and quality of life in HIV-
positive patients, its long-term usage can initiate toxic side-effects that
may lead to cardio-metabolic dysfunction. From a philosophical view
point, it is therefore imperative that clinicians be mindful of the
beneﬁt-harm paradigm of ARVs within the clinical setting. Here it is
vital to continue with the development of novel ARV drugs with less
Fig. 4.Unifyingmodel how long-termHIV PI exposure can result in the onset of cardiovascular complications. HIV PIs can trigger ROS production (as explained in Fig. 2) that may result in
the impairment of UPS function. UPS activity may also be directly inhibited by HIV PIs by competitive binding. Blunted UPS will lead to attenuated degradation of key proteins and also
increase overall intracellular oxidative stress leading to downstreameffects, e.g. decreasedmitochondrial respiration and lowerATP generation.UCP activationwill diminish themitochon-
drial membrane potential and also contribute to reduced ATP production. Higher ROS levelsmay also contribute to ER stress, endothelial dysfunction and the onset of atherosclerosis. Im-
paired UPS functioning will lead to downstream effects at the transcriptional level, with enhanced SREBP binding to promoters of target lipogenic and cholesterogenic genes. This will
further fuel the pro-atherogenic milieu and result in the onset of CVD. Dysregulation of the UPS may also interfere with ionic channel function and electrical signal transfer between
cells (e.g. connexin 43) and thusmore directly impair cardiac contractility. PI—protease inhibitor, ROS—reactive oxygen species, UPS—ubiquitin proteasome system, ER—endoplasmic reticulum,
SREBP—sterol regulatory element binding protein, UCP—uncoupling protein, Δψm—mitochondrial membrane potential.
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larmechanismswhereby HAART (and speciﬁcally PIs) can elicit damag-
ing side-effects are of the utmost importance.Acknowledgements
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